Carcinoid Heart Disease

Progress in Cardiovascular Diseases

Volumn 49, Issue 6, 2007, Pages 439-451

  Bernheim, Alain M ^a   Connolly, Heidi M ^a   Hobday, Timothy J ^a   Abel, Martin D ^a   Pellikka, Patricia A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; OCTREOTIDE;

ARTICLE; CARCINOID SYNDROME; DISEASE CONTROL; DISEASE COURSE; HEART SURGERY; HEART VALVE REPLACEMENT; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; SURVIVAL TIME; SYSTEMIC DISEASE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; CARCINOID HEART DISEASE; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR AGENTS; ECHOCARDIOGRAPHY, DOPPLER, COLOR; EMBOLIZATION, THERAPEUTIC; FLUID THERAPY; HEPATECTOMY; HUMANS; HYDROXYINDOLEACETIC ACID; MALIGNANT CARCINOID SYNDROME; PROGNOSIS; TREATMENT OUTCOME; URINALYSIS;

EID: 34247847858     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2006.12.002     Document Type: Article

References (79)

1. Modlin I.M., and Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 79 (1997) 813-829
2. Kulke M.H., and Mayer R.J. Carcinoid tumors. N Engl J Med 340 (1999) 858-868
3. Lundin L., Norheim I., Landelius J., et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77 (1988) 264-269
4. Thorson A., Biorck G., Bjorkman G., et al. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 47 (1954) 795-817
5. Mason R.A., and Steane P.A. Anaesthesia for a patient with carcinoid syndrome. Anaesthesia 31 (1976) 243-246
6. Isler P., and Hedinger C. Metastatic carcinoid of the small intestine with severe valvular defects especially in the right part of the heart and with pulmonary stenosis; a peculiar symptom complex. Schweiz Med Wochenschr 83 (1953) 4-7
7. Pellikka P.A., Tajik A.J., Khandheria B.K., et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 87 (1993) 1188-1196
8. Roberts W.C. A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol 80 (1997) 251-256
9. Ferrans V.J., and Roberts W.C. The carcinoid endocardial plaque; an ultrastructural study. Hum Pathol 7 (1976) 387-409
10. Simula D.V., Edwards W.D., Tazelaar H.D., et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 77 (2002) 139-147
11. Ross E.M., and Roberts W.C. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 79 (1985) 339-354
12. Moertel C.G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1 (1983) 727-740
13. Chaowalit N., Connolly H.M., Schaff H.V., et al. Carcinoid heart disease associated with primary ovarian carcinoid tumor. Am J Cardiol 93 (2004) 1314-1315
14. Wilkowske M.A., Hartmann L.C., Mullany C.J., et al. Progressive carcinoid heart disease after resection of primary ovarian carcinoid. Cancer 73 (1994) 1889-1891
15. Bernheim A.M., Connolly H.M., and Pellikka P.A. Carcinoid heart disease in patients without hepatic metastases. Am J Cardiol 99 (2007) 292-294
16. Connolly H.M., Schaff H.V., Mullany C.J., et al. Surgical management of left-sided carcinoid heart disease. Circulation 104 Suppl I (2001) 36I-40I
17. Robiolio P.A., Rigolin V.H., Wilson J.S., et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92 (1995) 790-795
18. Moller J.E., Connolly H.M., Rubin J., et al. Factors associated with progression of carcinoid heart disease. N Engl J Med 348 (2003) 1005-1015
19. Denney W.D., Kemp Jr. W.E., Anthony L.B., et al. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 32 (1998) 1017-1022
20. Khan M.A., Herzog C.A., St Peter J.V., et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 339 (1998) 713-718
21. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
22. Rajamannan N.M., Caplice N., Anthikad F., et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 10 (2001) 827-831
23. Gustafsson B.I., Tommeras K., Nordrum I., et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111 (2005) 1517-1522
24. Waltenberger J., Lundin L., Oberg K., et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 142 (1993) 71-78
25. Norheim I., Oberg K., Theodorsson-Norheim E., et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206 (1987) 115-125
26. Nilsson J., von Euler A.M., and Dalsgaard C.J. Stimulation of connective tissue cell growth by substance P and substance K. Nature 315 (1985) 61-63
27. Pandya U.H., Pellikka P.A., Enriquez-Sarano M., et al. Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients. J Am Coll Cardiol 40 (2002) 1328-1332
28. Westberg G., Wangberg B., Ahlman H., et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 88 (2001) 865-872
29. Moller J.E., Pellikka P.A., Bernheim A.M., et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 112 (2005) 3320-3327
30. Kvols L.K. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci 733 (1994) 464-470
31. Feldman J.M. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 32 (1986) 840-844
32. Moertel C.G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5 (1987) 1502-1522
33. Rosen S. Grand rounds at the clinical center. JAMA 259 (1988) 267
34. Rubin J., Ajani J., Schirmer W., et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17 (1999) 600-606
35. Richter G., Stockmann F., Conlon J.M., et al. Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology 91 (1986) 612-618
36. Tomassetti P., Migliori M., Simoni P., et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 13 (2001) 55-58
37. Zuetenhorst J.M., Bonfrer J.M., Korse C.M., et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 97 (2003) 1609-1615
38. Kubota A., Yamada Y., Kagimoto S., et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93 (1994) 1321-1325
39. Kvols L.K., Moertel C.G., O'Connell M.J., et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315 (1986) 663-666
40. Eriksson B., and Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 10 Suppl S (1999) 31S-38S
41. Leong W.L., and Pasieka J.L. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 79 (2002) 180-187
42. Ansell S.M., Pitot H.C., Burch P.A., et al. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 (2001) 1543-1548
43. Oberg K., Norheim I., Lundqvist G., et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU. Acta Oncol 26 (1987) 429-432
44. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12 Suppl S (2001) 111S-114S
45. Kvols L.K., and Reubi J.C. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 32 (1993) 197-201
46. Ritzel U., Leonhardt U., Stockmann F., et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 90 (1995) 627-631
47. Ansell S.M., Mahoney M.R., Green E.M., et al. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol 27 (2004) 232-235
48. Jugdutt B.I., Watanabe M., and Turner F.W. Hepatic artery ligation in treatment of carcinoid syndrome. Can Med Assoc J 112 (1975) 325-327
49. Eriksson B.K., Larsson E.G., Skogseid B.M., et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 (1998) 2293-2301
50. Ruszniewski P., Rougier P., Roche A., et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71 (1993) 2624-2630
51. Ahlman H., Westberg G., Wangberg B., et al. Treatment of liver metastases of carcinoid tumors. World J Surg 20 (1996) 196-202
52. Brown K.T., Koh B.Y., Brody L.A., et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10 (1999) 397-403
53. Ahlman H., Wangberg B., Jansson S., et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 62 Suppl 1 (2000) 59-68
54. Sutcliffe R., Maguire D., Ramage J., et al. Management of neuroendocrine liver metastases. Am J Surg 187 (2004) 39-46
55. Osborne D.A., Zervos E.E., Strosberg J., et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13 (2006) 572-581
56. Grazi G.L., Cescon M., Pierangeli F., et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 47 (2000) 481-486
57. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445
58. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 (2003) 29-37
59. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169 (1995) 36-42
60. McEntee G.P., Nagorney D.M., Kvols L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 (1990) 1091-1096
61. Connolly H.M., Nishimura R.A., Smith H.C., et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 25 (1995) 410-416
62. Connolly H.M., and Pellikka P.A. Carcinoid heart disease. Curr Cardiol Rep 8 (2006) 96-101
63. McDonald M.L., Nagorney D.M., Connolly H.M., et al. Carcinoid heart disease and carcinoid syndrome: successful surgical treatment. Ann Thorac Surg 67 (1999) 537-539
64. Caplin M.E., Buscombe J.R., Hilson A.J., et al. Carcinoid tumour. Lancet 352 (1998) 799-805
65. Mason R.A., and Steane P.A. Carcinoid syndrome: its relevance to the anaesthetist. Anaesthesia 31 (1976) 228-242
66. Vaughan D.J., and Brunner M.D. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 35 (1997) 129-142
67. Propst J.W., Siegel L.C., and Stover E.P. Anesthetic considerations for valve replacement surgery in a patient with carcinoid syndrome. J Cardiothorac Vasc Anesth 8 (1994) 209-212
68. Claure R.E., Drover D.D., Haddow G.R., et al. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management. Can J Anaesth 47 (2000) 334-337
69. Marsh H.M., Martin Jr. J.K., Kvols L.K., et al. Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology 66 (1987) 89-91
70. Neustein S.M., and Cohen E. Anesthesia for aortic and mitral valve replacement in a patients with carcinoid heart disease. Anesthesiology 82 (1995) 1067-1070
71. Hamid S.K., and Harris D.N. Hypotension following valve replacement surgery in carcinoid heart disease. Anaesthesia 47 (1992) 490-492
72. Quinlivan J.K., and Roberts W.A. Intraoperative octreotide for refractory carcinoid-induced bronchospasm. Anesth Analg 78 (1994) 400-402
73. Connolly H.M., Schaff H.V., Mullany C.J., et al. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation 106 Suppl I (2002) 51I-56I
74. DiSesa V.J., Mills Jr. R.M., and Collins Jr. J.J. Surgical management of carcinoid heart disease. Chest 88 (1985) 789-791
75. Ridker P.M., Chertow G.M., Karlson E.W., et al. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J 121 (1991) 1835-1838
76. Schoen F.J., Hausner R.J., Howell J.F., et al. Porcine heterograft valve replacement in carcinoid heart disease. J Thorac Cardiovasc Surg 81 (1981) 100-105
77. Thorburn C.W., Morgan J.J., Shanahan M.X., et al. Long-term results of tricuspid valve replacement and the problem of prosthetic valve thrombosis. Am J Cardiol 51 (1983) 1128-1132
78. Himelman R.B., and Schiller N.B. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol 63 (1989) 347-352
79. Robiolio P.A., Rigolin V.H., Harrison J.K., et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 75 (1995) 485-488